[go: up one dir, main page]

WO2003047524A3 - Methodes et compositions permettant la modulation du systeme immunitaire et utilisations de celles-ci - Google Patents

Methodes et compositions permettant la modulation du systeme immunitaire et utilisations de celles-ci Download PDF

Info

Publication number
WO2003047524A3
WO2003047524A3 PCT/US2002/038415 US0238415W WO03047524A3 WO 2003047524 A3 WO2003047524 A3 WO 2003047524A3 US 0238415 W US0238415 W US 0238415W WO 03047524 A3 WO03047524 A3 WO 03047524A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
present
immune system
ameliorating
treating
Prior art date
Application number
PCT/US2002/038415
Other languages
English (en)
Other versions
WO2003047524A2 (fr
Inventor
Lan Bo Chen
Daniel Auclair
Stine-Kathrein Kraeft
Original Assignee
Dana Farber Cancer Inst Inc
Lan Bo Chen
Daniel Auclair
Stine-Kathrein Kraeft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Lan Bo Chen, Daniel Auclair, Stine-Kathrein Kraeft filed Critical Dana Farber Cancer Inst Inc
Priority to CA002468698A priority Critical patent/CA2468698A1/fr
Priority to AU2002359560A priority patent/AU2002359560A1/en
Priority to JP2003548785A priority patent/JP2005518366A/ja
Priority to EP02794106A priority patent/EP1455775A2/fr
Publication of WO2003047524A2 publication Critical patent/WO2003047524A2/fr
Publication of WO2003047524A3 publication Critical patent/WO2003047524A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes permettant de prévenir, de traiter ou d'améliorer un ou plusieurs symptômes de troubles pour lesquels une modulation du système immunitaire du sujet est bénéfique, par l'administration d'un agent inducteur de tissu lymphoïde et d'un agent immunomodulateur. L'invention concerne en particulier des méthodes permettant la prévention, la traitement ou l'amélioration d'une pathologie proliférative, d'une maladie infectieuse, d'une maladie cardio-vasculaire, d'une maladie auto-immune, d'un trouble inflammatoire, ou d'un ou de plusieurs symptômes de ceux-ci. Cette méthode consiste à administrer à un sujet nécessitant un tel traitement, un ou plusieurs agents inducteurs de tissu lymphoïde et un ou plusieurs agents immunomodulateurs. L'invention concerne également des compositions et des articles fabriqués, destinés à prévenir, à traiter ou à améliorer un ou plusieurs symptômes associés à des troubles pour lesquels une modulation du système immunitaire est bénéfique, comprenant notamment, mais non exclusivement, les pathologies prolifératives, les maladies infectieuses, les maladies cardio-vasculaires, les troubles auto-immuns et les troubles inflammatoires. L'invention concerne en outre des procédés de criblage et d'identification d'agents inducteurs du tissu lymphoïde et/ou d'agents immunomodulateurs.
PCT/US2002/038415 2001-11-30 2002-12-02 Methodes et compositions permettant la modulation du systeme immunitaire et utilisations de celles-ci WO2003047524A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002468698A CA2468698A1 (fr) 2001-11-30 2002-12-02 Methodes et compositions permettant la modulation du systeme immunitaire et utilisations de celles-ci
AU2002359560A AU2002359560A1 (en) 2001-11-30 2002-12-02 Methods and compositions for modulating the immune system and uses thereof
JP2003548785A JP2005518366A (ja) 2001-11-30 2002-12-02 免疫系を調節するための方法および組成物、並びにその使用
EP02794106A EP1455775A2 (fr) 2001-11-30 2002-12-02 Methodes et compositions permettant la modulation du systeme immunitaire et utilisations de celles-ci

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33412101P 2001-11-30 2001-11-30
US60/334,121 2001-11-30

Publications (2)

Publication Number Publication Date
WO2003047524A2 WO2003047524A2 (fr) 2003-06-12
WO2003047524A3 true WO2003047524A3 (fr) 2003-09-12

Family

ID=23305676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038415 WO2003047524A2 (fr) 2001-11-30 2002-12-02 Methodes et compositions permettant la modulation du systeme immunitaire et utilisations de celles-ci

Country Status (7)

Country Link
US (2) US20040022869A1 (fr)
EP (1) EP1455775A2 (fr)
JP (1) JP2005518366A (fr)
AU (1) AU2002359560A1 (fr)
CA (1) CA2468698A1 (fr)
TW (1) TW200408407A (fr)
WO (1) WO2003047524A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260241T3 (es) * 2000-06-29 2006-11-01 Biosyntech Canada Inc. Composicion y procedimiento para la reparacion y regeneracion de cartilago y otros tejidos.
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
US8394422B2 (en) * 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
FR2838965B1 (fr) * 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
AU2003230181A1 (en) * 2002-05-21 2003-12-02 Yeda Research And Development Co. Ltd. Dna vaccines encoding heat shock proteins
US8071321B2 (en) * 2002-08-29 2011-12-06 Cytocure Llc Methods for up-regulating antigen expression in tumors
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
JP5362986B2 (ja) 2004-06-23 2013-12-11 シンタ ファーマスーティカルズ コーポレイション 癌治療のためのビス（チオ‐ヒドラジドアミド）塩
WO2006028634A2 (fr) * 2004-09-01 2006-03-16 Vijay Ramakrishnan Pegylation specifique de site d'anticorps largement neutralisant diriges contre le vhc et leur utilisation pour le traitement d'infections chroniques par vhc
US20060142393A1 (en) * 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
AU2005306471B2 (en) * 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
CA2593084C (fr) 2004-12-30 2014-03-18 Bioresponse, Llc Utilisation d'indoles lies au diindolylmethane dans le traitement et la prevention d'etats associes au virus respiratoire syncytial
JP2006213645A (ja) * 2005-02-03 2006-08-17 Hokkaido Univ ゲラニルゲラニルアセトンと抗癌剤とを組み合わせてなる医薬
EP2634252B1 (fr) 2005-02-11 2018-12-19 University of Southern California Procédé d'expression de protéines avec des ponts disulfures
JP2008536870A (ja) * 2005-04-15 2008-09-11 シンタ ファーマシューティカルズ コーポレーション 治療のためのナチュラルキラー細胞活性増強法
EP1877048A1 (fr) * 2005-04-15 2008-01-16 Synta Pharmaceuticals Corporation Polytherapie anticancereuse avec des composes bis(thiohydrazide) amide
AU2006242540A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG of 17-AG of a prodrug of either
EP1721615A1 (fr) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Composition pharmaceutique comprenant de l'arsenite de sodium ou de potassium pour traiter le cancer urogenital et ses métastases
AU2006247470B2 (en) * 2005-05-16 2010-04-01 Synta Pharmaceuticals Corp. Synthesis of bis(thio-hydrazide amide) salts
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
AU2006279891B2 (en) * 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
WO2007067752A2 (fr) * 2005-12-08 2007-06-14 Cytokinetics, Inc. Compositions et procedes de traitement
US8007796B2 (en) * 2005-12-16 2011-08-30 Micromet Ag Means and methods for the treatment of tumorous diseases
EP2029156A4 (fr) * 2006-05-01 2010-07-21 Univ Southern California Polythérapie pour traiter le cancer
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
EP2061451A2 (fr) * 2006-08-21 2009-05-27 Synta Pharmaceuticals Corporation Traitement du mélanome par des bis(thio-hydrazide amides)
AU2007288336B2 (en) * 2006-08-21 2011-04-21 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
CA2660524A1 (fr) 2006-08-21 2008-02-28 Synta Pharmaceutical Corp. Composes servant a traiter des troubles proliferatifs
US7939564B2 (en) 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
WO2008033494A2 (fr) * 2006-09-15 2008-03-20 Synta Pharmaceuticals Corp. Purification de bis(thiohydrazide amides)
GB0624745D0 (en) * 2006-12-11 2007-01-17 Univ Sheffield Acetylation
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
EP2170311A4 (fr) * 2007-05-16 2011-10-19 Avalon Pharmaceuticals Compositions et procédés pour traiter ou empêcher des maladies auto-immunes
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
LT2475362T (lt) * 2009-09-10 2019-06-10 Kominox, Inc. Tikslinė vėžinių kamieninių ląstelių ir atsparaus vaistams vėžio terapija
WO2012088525A2 (fr) * 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Méthodes de traitement de copd
CN102526610A (zh) * 2011-12-20 2012-07-04 宋涛 一种治疗多发性大动脉炎的中药
WO2013130242A1 (fr) * 2012-02-29 2013-09-06 Coyote Pharmaceuticals, Inc. Formulations de géranylgéranylacétone
JP2015514686A (ja) 2012-02-29 2015-05-21 コヨーテ・ファーマシューティカルズ・インコーポレイテッドＣｏｙｏｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｇａ及びそのｇｇａ誘導体組成物並びにこれらを含む麻痺状態を含めた神経変性疾患を治療する方法
US9681647B2 (en) 2012-07-05 2017-06-20 Cornell University Mammal with an orthotopic tumor capable of metastasis, a method of making and a method of using
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
RU2547082C1 (ru) * 2014-03-19 2015-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения метастатического поражения головного мозга
WO2018056905A1 (fr) * 2016-09-20 2018-03-29 Nanyang Technological University Co-cristaux de nurr1-lbd dans un complexe avec une prostaglandine cyclopenténone et des modulateurs de nurr1
EP3609873A1 (fr) 2017-01-17 2020-02-19 Forrest, Michael, David Inhibiteurs thérapeutiques du mode inverse de l'atp synthase
US12337000B2 (en) 2017-07-13 2025-06-24 Michael David FORREST Therapeutic modulators of the reverse mode of ATP synthase
CN109745545A (zh) * 2019-01-30 2019-05-14 河北师范大学 环孢素a在和热疗联合应用治疗宫颈癌的药物中的应用
US11369473B2 (en) * 2019-04-08 2022-06-28 Loubert S. Suddaby Extended release immunomodulatory implant to facilitate bone morphogenesis
US11779683B2 (en) 2019-04-08 2023-10-10 Loubert S. Suddaby Extended release immunomodulatory implant to facilitate bone morphogenesis
CN112358545B (zh) * 2020-11-10 2022-03-01 中国农业大学 鸽毛滴虫与白色念珠菌二联卵黄抗体粉的制备方法及应用
AU2021421391A1 (en) 2021-01-24 2023-07-20 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965718A (en) * 1997-10-24 1999-10-12 The Scripps Research Institute Analogs of sarcodictyin and eleutherobin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6040138A (en) * 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5010099A (en) * 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US4939168A (en) * 1989-08-11 1990-07-03 Harbor Branch Oceanographics Institution, Inc. Discodermolide compounds, compositions containing same and methods of preparation and use
US5861424A (en) * 1991-04-26 1999-01-19 Dana Farber Cancer Institute Composition and method for treating cancer
NO923126L (no) * 1991-08-13 1993-02-15 Fuji Photo Film Co Ltd Preparat og metode for behandling av canser
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5618831A (en) * 1992-11-17 1997-04-08 Fuji Photo Film Co., Ltd. Composition and method for treating cancer
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP1386922B1 (fr) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthèse d'épitholones, intermédiaires, analogues et leur utilisation
JP2002502588A (ja) * 1998-02-06 2002-01-29 アフィメトリックス インコーポレイテッド 製造プロセスにおける品質管理の方法
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965718A (en) * 1997-10-24 1999-10-12 The Scripps Research Institute Analogs of sarcodictyin and eleutherobin

Also Published As

Publication number Publication date
AU2002359560A1 (en) 2003-06-17
JP2005518366A (ja) 2005-06-23
US20040022869A1 (en) 2004-02-05
WO2003047524A2 (fr) 2003-06-12
CA2468698A1 (fr) 2003-06-12
EP1455775A2 (fr) 2004-09-15
TW200408407A (en) 2004-06-01
US20080089950A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2003047524A3 (fr) Methodes et compositions permettant la modulation du systeme immunitaire et utilisations de celles-ci
HK1052301A1 (zh) α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途
WO1999064059A3 (fr) Utilisation de la secretine pour le traitement de l'autisme et d'autres troubles du comportement, troubles neurologiques ou immunologiques
EP1992643A3 (fr) Compositions et procédés pour le traitement et le diagnostic d'une tumeur
WO2002069904A3 (fr) Prevention ou traitement de maladies inflammatoires ou auto-immunes par administration d'antagonistes de cd2 en combinaison avec d'autres agents prophylactiques ou therapeutiques
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
CA2274596A1 (fr) Compositions et procedes servant a ameliorer le fonctionnement gastro-intestinal
WO2004041067A3 (fr) Prevention et traitement d'une maladie synucleopathique
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
EP1409544A4 (fr) Anticorps humains du dr4 et utilisations
MX348062B (es) Mutantes que degradan proteoglicanos para tratamiento del snc.
IL132293A0 (en) Use of lactoferin in the treatment of allergen induced disorders
WO2006110760A3 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
WO2001058476A3 (fr) Procedes et compositions pour le traitement de la maladie d'alzheimer par le renforcement de l'activite de la plasmine ou de l'activite du type de la plasmine
WO1999032634A3 (fr) Compositions derivees de mycobacterium vaccae et leurs methodes d'utilisation
WO2002030354A3 (fr) Traitement a base d'uridine destine a des patients presentant des taux eleves de purine
WO2003049667A3 (fr) Methode de traitement du cancer
PL375113A1 (en) Casein derived peptides and uses thereof in therapy
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
TR200200278T2 (tr) Kalsilitik bileşimler
IL158152A0 (en) Osteoprotegerin in milk
WO2002081508A3 (fr) Utilisation de molecules de liaison cd25 chez des patients resistants aux steroides
WO2001004318A3 (fr) Nouveaux genes de virus de la myxomatose pour immunomodulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2468698

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003548785

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002359560

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002794106

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002794106

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002794106

Country of ref document: EP